Window of opportunity studies: Do they fulfil our expectations?

Area of Science:

• Oncology
• Clinical Trial Design
• Translational Research

Background:

• Window of opportunity studies involve administering novel therapeutic agents to patients between diagnosis and standard treatment, typically in cancer treatment-naïve individuals.
• These trials facilitate the collection of pre- and post-treatment tumor biopsies and imaging for in-depth translational research.

Purpose of the Study:

• To evaluate the advantages and disadvantages of window of opportunity studies in cancer drug development.
• To discuss the optimal design considerations for these unique clinical trials, focusing on breast and head and neck cancers.

Main Methods:

• Review and discussion of the design principles for window of opportunity studies.
• Analysis of potential benefits, including expedited drug development and biomarker identification.
• Examination of drawbacks such as safety concerns, logistical complexities, and delayed standard care.

Main Results:

• Window of opportunity studies can accelerate the understanding of pharmacodynamic parameters and identify predictive biomarkers.
• These trials may expedite the development of new cancer therapies by providing early translational insights.
• Potential drawbacks include risks to patient safety, logistical hurdles, and the possibility of delaying definitive treatment.

Conclusions:

• Window of opportunity studies present a valuable, albeit complex, paradigm for early-phase cancer drug development.
• Careful consideration of study design is crucial to mitigate risks and maximize the scientific and clinical benefits.
• Further research and discussion are warranted to refine the application of these studies in oncology.